GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sigyn Therapeutics Inc (OTCPK:SIGY) » Definitions » Quick Ratio

Sigyn Therapeutics (Sigyn Therapeutics) Quick Ratio : 0.02 (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Sigyn Therapeutics Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Sigyn Therapeutics's quick ratio for the quarter that ended in Mar. 2024 was 0.02.

Sigyn Therapeutics has a quick ratio of 0.02. It indicates that the company cannot currently fully pay back its current liabilities.

The historical rank and industry rank for Sigyn Therapeutics's Quick Ratio or its related term are showing as below:

SIGY' s Quick Ratio Range Over the Past 10 Years
Min: 0.01   Med: 0.03   Max: 1.44
Current: 0.02

During the past 10 years, Sigyn Therapeutics's highest Quick Ratio was 1.44. The lowest was 0.01. And the median was 0.03.

SIGY's Quick Ratio is ranked worse than
99.03% of 1546 companies
in the Biotechnology industry
Industry Median: 3.595 vs SIGY: 0.02

Sigyn Therapeutics Quick Ratio Historical Data

The historical data trend for Sigyn Therapeutics's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sigyn Therapeutics Quick Ratio Chart

Sigyn Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.14 0.47 0.01 0.02

Sigyn Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.13 0.02 0.03 0.02 0.02

Competitive Comparison of Sigyn Therapeutics's Quick Ratio

For the Biotechnology subindustry, Sigyn Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sigyn Therapeutics's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sigyn Therapeutics's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Sigyn Therapeutics's Quick Ratio falls into.



Sigyn Therapeutics Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Sigyn Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(0.118-0.05)/3.608
=0.02

Sigyn Therapeutics's Quick Ratio for the quarter that ended in Mar. 2024 is calculated as

Quick Ratio (Q: Mar. 2024 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(0.134-0.05)/4.235
=0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sigyn Therapeutics  (OTCPK:SIGY) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Sigyn Therapeutics Quick Ratio Related Terms

Thank you for viewing the detailed overview of Sigyn Therapeutics's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sigyn Therapeutics (Sigyn Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
2468 Historic Decatur Road, Suite 140, San Diego, CA, USA, 92106
Sigyn Therapeutics Inc is a development-stage therapeutic technology company. Its business focus is the clinical advancement of Sigyn Therapy, a multi-function blood purification technology designed to overcome the limitations of previous drugs and devices to treat life-threatening inflammatory disorders, including sepsis, the leading cause of hospital deaths worldwide. To support widespread implementation, the company designed Sigyn Therapy to be a single-use disposable device that is deployable on the global infrastructure of hemodialysis and continuous renal replacement therapy machines already located in hospitals and clinics.
Executives
Joseph Segelman director, 10 percent owner, officer: President & CEO 9190 W OLYMPIC BLVD, # 263, BEVERLY HILLS CA 90212
Australian Sapphire Corp 10 percent owner 9190 W OLYMPIC BLVD, BEVERLY HILLS CA 90212
Chaya Segelman director, officer: Secretary 9190 W OLYMPIC BLVD, # 263, BEVERLY HILLS CA 90212